Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective study.

[1]  T. Polascik,et al.  Characteristics of patients diagnosed with both melanoma and renal cell cancer , 2013, Cancer Causes & Control.

[2]  A. Webster,et al.  Cancer in the transplant recipient. , 2013, Cold Spring Harbor perspectives in medicine.

[3]  J. Sosman,et al.  Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  B. Escudier,et al.  Emerging immunotherapies for renal cell carcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  D. Schadendorf,et al.  Advances and perspectives in immunotherapy of melanoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[7]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[8]  A. Israni,et al.  Spectrum of cancer risk among US solid organ transplant recipients. , 2011, JAMA.

[9]  S. Puig,et al.  A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma , 2011, Nature.

[10]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[11]  J. Patard,et al.  Characteristics of the coexistence of melanoma and renal cell carcinoma , 2010, Cancer.

[12]  S. Swetter,et al.  Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study. , 2010, Journal of the American Academy of Dermatology.

[13]  M. Tucker,et al.  Increased risk of second primary cancers after a diagnosis of melanoma. , 2010, Archives of dermatology.

[14]  M. Falster,et al.  Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis , 2007, The Lancet.

[15]  G. Morgan,et al.  Non-Hodgkin Lymphoma Secondary to Cancer Chemotherapy , 2007, Cancer Epidemiology Biomarkers & Prevention.

[16]  J. Yang,et al.  Immunotherapy for renal cell cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Travis,et al.  The Epidemiology of Second Primary Cancers , 2006, Cancer Epidemiology Biomarkers & Prevention.

[18]  C. Beisland,et al.  Multiple primary malignancies in patients with renal cell carcinoma: a national population‐based cohort study , 2006, BJU international.

[19]  I. M. Jones,et al.  Second cancers after radiotherapy: any evidence for radiation-induced genomic instability? , 2003, Oncogene.

[20]  B. Kohler,et al.  Multiple primary cancers of the ovary in the United States, 1992–1997 , 2003, Cancer.

[21]  W. Clark,et al.  Surveillance Bias and the Excess Risk of Malignant Melanoma among Employees of the Lawrence Livermore National Laboratory , 1993, Epidemiology.

[22]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[23]  Epidemiologic Perspectives & Innovations BioMed Central Methodology , 2008 .

[24]  J. Kaldor,et al.  Secondary malignancies following cancer chemotherapy. , 1994, Acta oncologica.

[25]  I. Penn.  Tumors of the immunocompromised patient. , 1988, Annual review of medicine.